News - HanchorBio

HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration

HanchorBio announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio's expertise in innovative drug development and clinical development with KMUH's clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.

Nov 05, 2026

Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance

HanchorBio announced that its wholly owned subsidiary, FBD Biologics Limited, has received approval from the Taiwan Food and Drug Administration (TFDA) for the Investigational New Drug (IND) application for HCB303, a next-generation trispecific fusion protein featuring a differentiated TIGIT-Fc ligand-trap strategy.

Oct 30, 2026

HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy

HanchorBio announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.

Oct 27, 2026

HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026

HanchorBio announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.

Oct 27, 2026

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.

Oct 22, 2026

HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment

HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.

Oct 19, 2026

HanchorBio Expands HCB101 Colorectal Cancer Program in Taiwan as Early 2L CRC Data Show 50% ORR and 100% DCR

HanchorBio today announced that the first patient in Taiwan has been dosed in the colorectal cancer (CRC)-specific cohort of its global Phase 1b/2a HCB101-201 study (NCT06771622), expanding the Company’s global development program in second-line metastatic CRC.

Oct 14, 2026

HanchorBio Expands Global Pharma Engagement at BioJapan 2026

HanchorBio announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.

Oct 12, 2026

HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance

HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.

Oct 08, 2026

HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.

Oct 03, 2026